department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Nurix Therapeutics, Inc. ($NRIX) · pharmadog

PUBLIC COMPANY

$NRIXNurix Therapeutics, Inc.

Brisbane, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

2Phase 1

Adenocarcinoma Of The Gastroesophageal Junction

Diffuse Large B-Cell Lymphoma

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

16 open roles at Nurix Therapeutics, Inc. →

Where Nurix Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 16

departmentR&D / Discovery 4 Regulatory 4 Quality 3 Clinical 2 Medical Affairs 2 Market Access 1

News

no news has mentioned this company yet

identifiers

ticker

$NRIX

SEC CIK

0001549595

country

US

source

sec_tickers

top tags

DLBCL2 Oncology2 NSCLC1

mentioned in

0news items

entity-linker matched

$NRIX

Data sources

last refreshed 4m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase2A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)recruitingn=100
phase1A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignanciesrecruitingn=572
phase2Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignanciesnot yet recruitingn=150
phase3Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLnot yet recruitingn=620
phase1A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignanciesrecruitingn=248
phase1Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tabletsrecruitingn=18
phase1A Study of NX-1607 in Adults With Advanced Malignanciesrecruitingn=345
phase1A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjectscompletedn=32

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Apr 2, 26SELLRing Christine· Chief Legal Officer8,148 sh @ $15.24−$124K↗
Mar 2, 26SELLRing Christine· Chief Legal Officer8,148 sh @ $15.44−$126K↗
Feb 9, 26SELLRing Christine· Chief Legal Officer14,261 sh @ $16.66−$238K↗
Jan 30, 26SELLHansen Gwenn· Chief Scientific Officer4,797 sh @ $16.58−$80K↗
Jan 30, 26SELLRing Christine· Chief Legal Officer4,333 sh @ $16.58−$72K↗
Jan 30, 26SELLvan Houte Hans· Chief Financial Officer3,588 sh @ $16.58−$59K↗
Jan 30, 26SELLHansen Gwenn· Chief Scientific Officer98 sh @ $17.37−$2K↗
Jan 30, 26SELLRing Christine· Chief Legal Officer88 sh @ $17.37−$2K↗
Jan 30, 26SELLvan Houte Hans· Chief Financial Officer73 sh @ $17.37−$1K↗

routine RSU / option mechanics (6)

Feb 10, 26grantHansen Gwenn · Chief Scientific Officer93,750 sh
Feb 10, 26grantRing Christine · Chief Legal Officer42,875 sh
Feb 10, 26grantRing Christine · Chief Legal Officer93,750 sh
Feb 10, 26grantvan Houte Hans · Chief Financial Officer42,875 sh
Feb 10, 26grantSANDS ARTHUR T · President, CEO562,500 sh

Feb 10, 26

grant

van Houte Hans · Chief Financial Officer

93,750 sh